Abstract
BackgroundImmunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial positive...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have